VIA
VRDN icon

Virtus Investment Advisers’s Viridian Therapeutics VRDN Stock Holding History

Virtus Investment Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Buy
20,012
+11,573
+137% +$186K 0.09% 330
2026
Q1 		$165K Buy
8,439
+206
+3% +$6.12K 0.05% 436
2025
Q4 		$256K Buy
8,233
+971
+13% +$26.6K 0.07% 315
2025
Q3 		$157K Buy
7,262
+1,261
+21% +$22.7K 0.04% 369
2025
Q2 		$83.9K Sell
6,001
-3,128
-34% -$42.5K 0.03% 407
2025
Q1 		$123K Buy
+9,129
New +$155K 0.03% 390

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Virtus Investment Advisers's VRDN Position: Q2 2026 in Review

Virtus Investment Advisers increased its Viridian Therapeutics (VRDN) stake by 137% in Q2 2026, buying an estimated $186K and bringing the position to 20,012 shares worth $368K. The position accounts for 0.09% of the portfolio, ranked #330.

Virtus Investment Advisers first reported a position in VRDN in Q1 2025 and has held it in 6 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Virtus Investment Advisers held 20,012 shares of Viridian Therapeutics worth $368K as of Q2 2026.
  • Virtus Investment Advisers bought 11,573 Viridian Therapeutics shares in Q2 2026, an estimated $186K.
  • Viridian Therapeutics made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #330 holding.
  • Virtus Investment Advisers first reported a position in Viridian Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.